Recent prescription drug reforms have focused on lowering out-of-pocket costs through Medicare Part D redesign changes, negotiated drug pricing and annual spending caps.
At the same time, prescription discount programs that offer low-cost or free services, allowing individuals to pay directly for prescriptions outside traditional insurance, often through a discount card, are creating new questions for retirees trying to determine whether paying cash or using Medicare drug coverage provides better long-term value.
The topic has seen renewed attention following the rollout of additional direct-to-consumer prescription discount initiatives, including cash-pay prescription platforms, as Medicare beneficiaries also gain access to new prescription affordability protections.
The Question
How could cash-pay prescription discount programs affect Medicare beneficiaries?
The Answer
While some cash-pay prescription programs may offer lower prices at the pharmacy counter, beneficiaries may benefit from considering how those purchases interact with Medicare Part D coverage.
Under Medicare Part D, beneficiary spending on covered drugs purchased through plan pharmacies generally counts toward the annual out-of-pocket spending cap that eventually reduces prescription costs later in the year.
However, medications that aren't covered in the Medicare Part D plan typically don't count toward that annual spending cap for beneficiaries.
That means a beneficiary could save money on a prescription today — using a cash discount program — but also delay their progress in reaching the Medicare Part D cap later in the year.
According to the Centers for Medicare & Medicaid Services (CMS), Medicare beneficiaries generally accumulate spending toward annual Part D out-of-pocket limits only when covered prescriptions are purchased through their Medicare drug plans and participating network pharmacies.
This distinction could become increasingly important as beneficiaries continue adjusting to major Medicare Part D changes implemented through the Inflation Reduction Act.
What The 2026 Part D Changes Mean
According to CMS, the Medicare Part D annual out-of-pocket spending cap has increased from $2,000 in 2025 to $2,100 in 2026.
CMS also implemented the first negotiated Medicare drug prices Jan. 1, 2026, for 10 high-spending drugs covered under Medicare Part D.
The negotiated prices, known as maximum fair prices, apply to selected drugs without generic or biosimilar competition.
For some retirees, a discounted cash price may still represent the lowest immediate cost for a medication.
In some cases, cash-pay discount pricing may cost less than a beneficiary's Medicare copayment for the same drug.
But bypassing Medicare drug coverage could affect how quickly beneficiaries reach the annual spending cap available through their Part D plans.
The Medicare Prescription Payment Plan
This year, CMS expanded the Medicare Prescription Payment Plan, allowing beneficiaries to spread eligible Part D out-of-pocket costs across monthly payments during the plan year.
This means they don't have to pay the full amount at the pharmacy counter.
Some beneficiaries may not realize the program reduces upfront pharmacy costs but doesn't eliminate the full financial obligation — which could create confusion about ongoing monthly payment responsibilities.
As a result, some retirees may find themselves comparing:
◆ Medicare Part D pricing.
◆ Pharmacy cash pricing.
◆ Manufacturer discount programs.
◆ Third-party prescription discount platforms.
◆ Online direct-pay medication websites.
What Advisors Should Watch For
These expanding prescription drug shopping options are changing how some retirees evaluate their Medicare coverage decisions.
Medicare reforms, including insulin caps, vaccine coverage improvements and annual drug spending protections, have shifted the financial considerations for beneficiaries, but haven't simplified the choices.
For clients weighing cash-pay discount programs, the relevant question isn't just what a drug costs today at the pharmacy counter.
It's how that choice affects total spending across the full plan year.
A beneficiary who saves money on a prescription in February by bypassing Part D may delay reaching the $2,100 annual spending cap — and end up paying more overall when costs are tallied at year's end.
Advisors who understand these trade-offs can help clients make decisions that account for both immediate savings and long-term out-of-pocket exposure.
As more low-cost options enter the market, that kind of informed guidance matters more, not less.
Tricia Blazier is director of Healthcare Insurance Services at Allsup.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.